{"name":"Perceive Biotherapeutics, Inc.","slug":"perceive-biotherapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQVmw0aGxLZmEyNVI4aFRxR1FRbGZFdmMxTFQxX0JkYldZekkyZ1V4LW44WV8wV2ZrRzJFZFNjTENyMWNCYWh4ZU5tYU9vX1o3SGY4aGMtTUFKNEpqT3NheTlxcHFDLS05ZU9DUlJmUGJPT013TW1pUjR6b0JwR0U3WFZwaUpFUDVKTTFKejhlTkRsZW5KWDhrRzR2UjNvaFRVTnU3eU9nWEFKVjZsdUJSZ3pydDY1cEE3N3V2MHBOZFB5a2ZLWnZvdEFfUEx6MGlTM1pHQkRnVmNGa0o0YkhUN1JPVzZXOTFhNHdhMlRsUE9jQQ?oc=5","date":"2025-08-18","type":"pipeline","source":"Ophthalmology Times Europe","summary":"First clinical results demonstrate efficacy of VOY-101, a novel gene therapy for GA - Ophthalmology Times Europe","headline":"First clinical results demonstrate efficacy of VOY-101, a novel gene therapy for GA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQU2JRNGVZUnNZRVNTTzQxZEdDTUF5WEJya2Z3Vk1XSl9TSmZ0RTYyQzVDelBIeUU0Z0RLNk5YdGtVQmNYTEtOeTAxQWNEbXdWTGJDX2NlUzR0TmdFSVREQXNDT1o3SGtNNVZhMGQtTjBOZXZHczZZdHdzMy1HNU9QMzFrdld4dkhsemZpckNvenFkNm8yMWw2Z1hmZw?oc=5","date":"2025-02-26","type":"pipeline","source":"Ophthalmology Times","summary":"Perceive Pharma closes funding for $15M Series A therapy - Ophthalmology Times","headline":"Perceive Pharma closes funding for $15M Series A therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNOGVHTVIzM1pxcHZIVHg3b1dzTE9aMnNDbUFUOWJ0ZmZ0c1Q4Y1EtYXVGMGVXdnlKVk5uN2VObEtUcHZBUzk2OGgteGdaWkctajNrRDgwWUItWkVBb2R0QmZOWTVHd2pLdmZVM0h4X2N2TGpncGZqdzhwMDVZRzRuY3FCUkg1SjcxcDZrNkdPTXRWRC1EVlVXaUstbXYzbWh3MmtINGtn0gGrAUFVX3lxTFBTeEZIcUdFMkFkTG1ZMFRaV2kxbnN3ZzJoVmJDMGZBNjA5bXNseDFSYlljZzFBU3l4d1E2NzFXaFdiZW94akVZYnhBX1NuaVhYWG1RSUdFbG1TZmNndUhxb3loM2tyYkc1eGZfUk1qTGxHVldUcEFPUml1R1dJaDltUXczdVJJRkpoWHlicVdxR19XRVBMUndCbjZrUGlSajczZ2ZXcklTNnVVcw?oc=5","date":"2025-02-24","type":"pipeline","source":"Pulse 2.0","summary":"Perceive Pharma: $15 Million (Series A) Raised For Advancing Ophthalmic Neuroprotection - Pulse 2.0","headline":"Perceive Pharma: $15 Million (Series A) Raised For Advancing Ophthalmic Neuroprotection - Pulse 2.0","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPOGNDaDJ0S3NuWGhKbE9ZTVJ6Mml0bmQtMzlMYUZvcTRvUnFFWE5ENzhZVFUzR1VUbTJzbUc1Q3RXWkZKVnpTMkVoOGIxVG5rV3RnMmxkc0Vrb3h0Z0tObGdIZEdDMEZyemloVEw1RVJDaW4zejJtSUc0SDhtd0s5dmhwSVBDVENSMDAza1RpcG5MaGVzTjY5ZWN4Z0xGeElHaURsUzJ6bDNhM010MkpEZVZJXzVwVTFEaC1DVmo5V005b3pfaF9CUFkzSElYNVR3bXlqekx6c2o?oc=5","date":"2025-02-18","type":"pipeline","source":"PR Newswire","summary":"Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection - PR Newswire","headline":"Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNSF8xbF9kOFk3TzBRUzVFNVNFWGRLVFk1VUpiTXVfYWdUN3RyR2NMa1R3QTl1NnhjS0RpME84bHRzbmNieHhvd2JrZjlxazdZSDNHcVFTb3h2YW1jaEpSMjR6cGlSQldjSnJaVkE0NUNyY1FRRElpR1FUNU1Zenl5YVFSUUhmNTdOcmllbEVDZk5IV2xkbTBmcXlyUEh5eW5IZjZ2U2RhRVdSX0FqdzJ1NnNCN1dHYmJNRHk0NDNvNlNiZ0dfSjd5Z2VTaUpZb0dhU3V4a2JJel9RbllGY1E2b2c1d2tWdVh1elpFcW5WOUJfaF9tU3FLaDJ6c2UzUQ?oc=5","date":"2025-01-23","type":"trial","source":"PR Newswire","summary":"70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - PR Newswire","headline":"70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1vQUExMERQMElsRkhiNTVxSE1yWDc0aWFmM0tKQ0Z3eEVEVEJNUnhjdEdDNk9rUjJhSkxUMnFGUlFaM0d6ZUdubERxWkFYLUZjWm9VaWtvR1NMVHctR0NZ?oc=5","date":"2025-01-13","type":"trial","source":"Nature","summary":"Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial | Eye - Nature","headline":"Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related mac","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxOUVVGN0pqSktYbDVqOE12LWFaV0gwY1dBaW4welk1X3FwakJsTnM2ZEZwLVZJOWl0RUFlWEVjTzZEaEpIcmJyR215U1dFaVJlaGM1cDV2eU1lNGRYaS1adUlUdjF0MjhVSUlab0IxVlg2SUdmMkVXRnV0enlPTTI0YmtVUzZvR3hseHIwLWtRejd3VXl5eXZEejZnQU02TWFCLXByT21vMTJxdGNqY2hDMWFreDFYVnVHbnVSWFVlNkxya3FaN2VIczMyMFNDSktFakNSMkRtWFZpUVRNNVh0cGt5N0ZGVEo0NU1jVjFhNzNWbHNOWENlQ3E4S0kyaDVZaWhTM3d3Z0RKdlBYLUd0dWg1ajd3a1pnU2pnc2hCSVNfREY4RXB0dVJjYUpSY3I3cWhxUDdfZw?oc=5","date":"2024-10-28","type":"trial","source":"GlobeNewswire","summary":"Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ - GlobeNewswire","headline":"Complement Inhibitors Clinical Trial Pipeline Analysis: 40+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNX3Y4ZVFFaXNIdzB5ZWZIdzNVSHZIZms2UElwbGlwSV82TXZkem41VzVCVWVRYUZyVkg4UXNYVW05SXNzTUcxVFZNX1NpUVNlM1ppLWVnVDNjYm4zZThGYjhJYUNnSG1sSkxOakwtQ01OSGl5U2tEdWZSWUdudzFwaWVyb3JZNHRnZWxMc2ktZDc1djM2YjhsYlNnWkUzeFdhVGtuaGdwSUFnNDM0Z3lISDBiX0hmWVFDeGJ4SnRvaUtHVFpfYUtQdVdyNlllSC05RzNyNDRUTFEzVDNkblZyT1pmaGZrSDY2eWg5OVF2VVhhenpRM29INg?oc=5","date":"2024-09-20","type":"pipeline","source":"GlobeNewswire","summary":"Geographic Atrophy (GA) Market Size to Hit USD 50.0 Billion by 2032 with a 8.6% CAGR – SNS Insider - GlobeNewswire","headline":"Geographic Atrophy (GA) Market Size to Hit USD 50.0 Billion by 2032 with a 8.6% CAGR – SNS Insider","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxObHItWXVUNHRseTh3N05uVndpMWxua0t4OWFkNFl3bUxoS0V2LWgyYUtBSGZOSWo1OFhnVnVWdlIyeG5zWThNWTVQWjVFSEVnT2JuNU9IdnRnRGFKZnNmMXRHMTZLNmtSOU5EYUpzeDdaMWVmU1AwQ0tBa3FGUnFKQw?oc=5","date":"2023-01-06","type":"pipeline","source":"Crunchbase News","summary":"The Week’s 10 Biggest Funding Rounds: SpaceX Takes Off In New Year; Netskope Secures $401M - Crunchbase News","headline":"The Week’s 10 Biggest Funding Rounds: SpaceX Takes Off In New Year; Netskope Secures $401M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQOWtPV05ZTFlLa2ZNcVNhWXdxbFRYM1BPZHhNc2FqWm9oZnhudm5MWXRhcUJYeWVjZHMwbFVJZEtIa3JJX0RLd0RQVnRyM2t3d2JlcnN6Qjl4bF8tU2YtV0EwazFTczN2NlFROHBTSGxyWXVObFBQR1hBNDFPNDA1UXc3T29uYWhHTF9aOHpscGtNYXJMQ3FjZzlnVnFCQXMxQkk3Y2JhUjFSWHRnT2tYMVU0bEVKU0JKdHRxRnBwU3hDeXgzVzl1Sk1UWGJIQktFMmhUdWpaYXF4bnNX?oc=5","date":"2023-01-05","type":"pipeline","source":"PR Newswire","summary":"Perceive Biotherapeutics Attracts $78M Series B Financing to Advance Diversified Pipeline - PR Newswire","headline":"Perceive Biotherapeutics Attracts $78M Series B Financing to Advance Diversified Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxPT09FcGtveWpTaTk5dlZmV2R4MC01X2dmV05VMGE3NkZmbHZ3T1FWUnR5RXhlS2VKYl9JRzZTeTVjQndMeXRoejRMM0JYS3BLWW5aMDNscVZFYk0yNVNKbUpjLUVCdTRXQmJZR1JLbVBhTTAwQUR0SDZHVmQzcEdPUlhsd2EzQ1lFTXpoajFUbmtFMndPN0RyczNvWG1CaUVDVTlNaG5hUUg0N19lU1BVZUZ1LXk2MFRfOXd1OGhFQ19KNWpHdXI2clBlWERySU9pZFExRTNiMENDNlhOTXZ1a1pCem1PSzNKZnI1U0pqYnJPTW1BbkhueFV3YUF6WFpXNVR3?oc=5","date":"2022-05-18","type":"pipeline","source":"PR Newswire","summary":"Perceive Biotherapeutics Appoints Anne E. Fung MD, as Chief Medical Officer to Drive Transformational Clinical Programs - PR Newswire","headline":"Perceive Biotherapeutics Appoints Anne E. Fung MD, as Chief Medical Officer to Drive Transformational Clinical Programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNdnFCWVozZl9adDhRRUhEWDFJdXUxLUxyUDF5MFBLeEJJYjZqcXkxeHhTYjJZRzRrU0dVNkxIbFhwc0x2QS1CbHA4blR2dVFxcHJDalRIM3k2VWthUFFOeXlDMUk4Mmh4b0kwWVIzUF9PYy1jNDM2QWtZUDZscG1iZXFDZ2NZaXloTWpXeVEyUVR3VWVYTGZmTlRuV0tIOG84dEpmWEhrQkR0eGNB?oc=5","date":"2015-04-24","type":"pipeline","source":"Life Science Leader","summary":"Lessons Learned Help Pfizer Accelerate Biotherapeutic Development - Life Science Leader","headline":"Lessons Learned Help Pfizer Accelerate Biotherapeutic Development","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}